|
A multicenter phase II study of istiratumab (MM-141) plus nab-paclitaxel (A) and gemcitabine (G) in metastatic pancreatic cancer (MPC). |
|
|
Consulting or Advisory Role - ARMO Biosciences; EMD Serono; Halozyme; Incyte; Merrimack |
Research Funding - Acerta Pharma (Inst); Aduro Biotech (Inst); Celgene (Inst); ImClone Systems (Inst); Infinity Pharmaceuticals (Inst); Merck (Inst); Merrimack (Inst); PharmaEngine (Inst); PRISM BioLab (Inst); Seagen (Inst) |
|
|
|
Stock and Other Ownership Interests - Merrimack |
Research Funding - Merrimack |
Patents, Royalties, Other Intellectual Property - Merrimack |
Travel, Accommodations, Expenses - Merrimack |
|
|
|
Stock and Other Ownership Interests - Merrimack |
Research Funding - Merrimack |
Travel, Accommodations, Expenses - Merrimack |
|
|
Employment - Cubist; Merrimack |
Stock and Other Ownership Interests - Cubist; Merrimack |
Research Funding - Cubist; Merrimack |
Travel, Accommodations, Expenses - Cubist; Merrimack |
|
|
|
Stock and Other Ownership Interests - Merrimack |
Research Funding - Merrimack |
Patents, Royalties, Other Intellectual Property - Merrimack |
Travel, Accommodations, Expenses - Merrimack |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Merrimack |
Research Funding - Merrimack |
Patents, Royalties, Other Intellectual Property - Cell Medica |
Travel, Accommodations, Expenses - Merrimack |
|
|
|
Stock and Other Ownership Interests - Merrimack |
Research Funding - Merrimack |
Patents, Royalties, Other Intellectual Property - Merrimack |
Travel, Accommodations, Expenses - Merrimack |